---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002841"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:51:09.662537+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics reports preliminary Q4 2024 cash of ~$220M

## Summary
- As of Dec 31, 2024, cash, cash equivalents and investments approx $220M.
- Preliminary, unaudited; subject to change upon completion of year-end closing procedures.
- Full year 2024 financial results to be included in upcoming Form 10-K.

## SEC filing metadata
- accession: 0001104659-25-002841
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465925002841/0001104659-25-002841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465925002841/tm253008d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002841
- JSON: https://secwatch.observer/filing/0001104659-25-002841.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002841.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.